Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE
Latest Information Update: 22 Mar 2025
At a glance
- Drugs Atezolizumab (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Olaparib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms COGNITION-GUIDE
Most Recent Events
- 03 Jul 2023 Status changed from not yet recruiting to recruiting.
- 14 Jun 2023 Planned End Date changed from 1 Dec 2029 to 1 Dec 2030.
- 14 Jun 2023 Planned primary completion date changed from 1 Apr 2029 to 1 Mar 2030.